Sonidegib - Novartis

Drug Profile

Sonidegib - Novartis

Alternative Names: Erismodegib; Erismodegib-phosphate; LDE-225; NVP-LDE-225; Odomzo; Sonidegib-phosphate

Latest Information Update: 27 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Groupe Francophone des Myelodysplasies; Massachusetts General Hospital; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stanford University; University of Alabama at Birmingham
  • Class Antineoplastics; Biphenyl compounds; Morpholines; Phenyl ethers; Pyridines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer
  • Phase II Haematological malignancies; Medulloblastoma; Multiple myeloma; Solid tumours
  • Phase I/II Myelofibrosis; Pancreatic cancer
  • No development reported Breast cancer; Chronic myeloid leukaemia; Graft-versus-host disease; Liver cancer; Myelodysplastic syndromes; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer
  • Discontinued Basal cell nevus syndrome

Most Recent Events

  • 01 Aug 2018 Novartis completes a phase I trial in Myelodysplastic syndromes (Combination therapy) in France (PO) (NCT02323139)
  • 24 Jun 2018 Biomarkers information updated
  • 05 Jun 2018 Sonidegib is still in phase II trials for Basal cell cancer in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top